| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 210 |
| 1 | CARBOPLATIN | 210 |
| 2 | PACLITAXEL | 180 |
| 3 | METHOTREXATE SODIUM | 156 |
| 4 | CYCLOPHOSPHAMIDE | 145 |
| 5 | CYCLOPHOSPHAMIDE FOR INJECTION | 145 |
| 6 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 145 |
| 7 | METHOTREXATE | 145 |
| 8 | DEXAMETHASONE | 142 |
| 9 | DEXAMETHASONE 1.5 MG | 142 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | FLUOROESTRADIOL F 18 | 1 | 0.0455 |
| 1 | ACETAMINOPHEN, DEXBROMPHENIRAMINE MALEATE | 1 | 0.0154 |
| 2 | GEFITINIB | 119 | 0.0132 |
| 3 | AFATINIB | 81 | 0.0122 |
| 4 | ZONGERTINIB | 2 | 0.0120 |
| 5 | DEMECLOCYCLINE | 2 | 0.0088 |
| 6 | DORDAVIPRONE | 1 | 0.0078 |
| 7 | ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE | 1 | 0.0076 |
| 8 | REPOTRECTINIB | 2 | 0.0073 |
| 9 | TOVORAFENIB | 2 | 0.0061 |
| # | Drug class | Count |
|---|---|---|
| 0 | Kinase Inhibitor [EPC] | 353 |
| 1 | Platinum-based Drug [EPC] | 337 |
| 2 | Corticosteroid [EPC] | 293 |
| 3 | Microtubule Inhibitor [EPC] | 257 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 226 |
| 5 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 212 |
| 6 | Folate Analog Metabolic Inhibitor [EPC] | 200 |
| 7 | Alkylating Drug [EPC] | 194 |
| 8 | HER2/neu Receptor Antagonist [EPC] | 139 |
| 9 | Aromatase Inhibitor [EPC] | 134 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Protease Activator [EPC] | 1 | 0.0078 |
| 1 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 5 | 0.0033 |
| 2 | Nucleoside Analog Antifungal [EPC] | 4 | 0.0028 |
| 3 | Actinomycin [EPC] | 6 | 0.0027 |
| 4 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 17 | 0.0027 |
| 5 | HER2/neu Receptor Antagonist [EPC] | 139 | 0.0019 |
| 6 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 1 | 0.0017 |
| 7 | Vesicular Monoamine Transporter 2 Inhibitor [EPC] | 2 | 0.0016 |
| 8 | Microtubule Inhibitor [EPC] | 257 | 0.0015 |
| 9 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 6 | 0.0015 |